Oncogenic KRAS plays a crucial role in pancreatic ductal adenocarcinoma (PDAC) development and progression. However, the mechanism has not been clearly elucidated. RKIP is a tumor repressor, and loss of RKIP has been shown in PDAC. Here, we found that KRAS expression was inversely correlated with RKIP expression in PDAC fresh tissue regardless of the KRAS mutant status. The negative correlation between KRAS and RKIP was further confirmed in our PDAC tissue microarray. KRAS overexpression and RKIP downregulation were associated with poor clinical outcomes. Knockdown or overexpression of KRAS in PDAC cell lines robustly increased or decreased, respectively, RKIP protein and mRNA levels. Furthermore, the MAPK-ERK pathway was involved in the regulation of RKIP. KRAS-regulated RKIP expression, which in turn affected the expression of pivotal epithelial-mesenchymal transition (EMT) and apoptosis factors. The biological function of the KRAS-RKIP axis was demonstrated in human pancreatic cancer cells in vitro and in vivo. KRAS knockdown increased RKIP expression and inhibited metastasis and chemoresistance. Moreover, the feature of metastasis and chemoresistance was rescued in the KRASknockdown cells through the inhibition of RKIP by RNA interference. In conclusion, our studies demonstrate how KRAS inhibits the tumor suppressor RKIP, thus offering novel justification for targeting RKIP as a strategy to overcome KRAS-induced tumor metastasis and chemoresistance in PDAC.
Introduction
Pancreatic ductal adenocarcinoma (PDAC), the predominant form of pancreatic cancer, is one of the most lethal common cancers, with an overall 5-year survival rate of <5%. Although tremendous efforts have been made to search for therapeutic improvements, the prognosis remains poor because pancreatic cancer is usually diagnosed at an advanced stage and is resistant to chemotherapy. 1 The genes and pathways that cause malignant phenotype, such as metastasis and chemotaxis, have not been fully elucidated. Dysfunctional activation of the KRAS oncogene, present in >90% of PDAC cases, accelerates pancreatic intraepithelial neoplasia (PanIN) formation and the development of invasive and metastatic cancer. 2, 3 Moreover, KRAS activation is closely linked with reduced apoptosis and increased resistance to drug therapy 4 due to the activation of pro-survival pathways and the upregulation of anti-apoptotic factors. 5 Therefore, oncogenic KRAS activation is recognized as a signature event in PDAC, serving a critical role in tumor initiation and progression. Raf kinase inhibitory protein (RKIP; also known as PEBP1) belongs to the evolutionarily conserved phosphatidylethanolamine-binding protein family. RKIP was originally identified as a physiologically relevant inhibitor of the Raf-MEK-ERK pathway that inhibits the kinase activity of Raf-1 through direct binding to Raf-1. 6, 7 RKIP is widely expressed in most human tissues, and it has important physiological functions in processes such as neural development, cardiac function and spermatogenesis. 8, 9 Reduced RKIP expression has been shown to be associated with tumor progression and unfavorable prognosis in a variety of human malignant tumors. [10] [11] [12] RKIP has also been shown to be a metastasis suppressor gene, which plays a role in cell proliferation, differentiation, migration, motility and mitosis. [13] [14] [15] In addition, it has been demonstrated that RKIP sensitizes drugresistant tumor cells to drug-induced apoptosis. 16 Emerging evidence has demonstrated that progressive loss of RKIP is strongly associated with neoplastic transformation of the pancreas, aggressive characteristics of PDAC and the epithelialmesenchymal transition (EMT) in pancreatic cancer. 17 However, the function and regulation of RKIP in the initiation and progression of PDAC remain poorly understood. Importantly, RKIP binds to Raf-1 but not B-Raf; therefore, the ERK pathway can be phosphorylated regardless of RKIP status. 18 Interestingly, a mathematical model predicts RKIP phosphorylation inhibition by ERK, which implies a feedback loop. 19 However, no experiments have been performed to confirm these findings. In addition, oncogenic KRAS leads to persistent activation of downstream signaling pathways (MAPK/ERK and PI3K/AKT) that drive PDAC initiation, progression and maintenance, including cell cycle regulation, proliferation, differentiation, anti-apoptosis effects and metastasis. [20] [21] [22] [23] Based on these results, we investigated whether KRAS and downstream signaling pathways contribute to the regulation of RKIP in PDAC.
In our study, we first observed that RKIP expression was reversely correlated with KRAS expression in PDAC fresh tissue and in a PDAC tissue microarray. We further showed that KRAS-regulated RKIP expression through a mechanism involving the activation of the ERK signaling pathway. Furthermore, in vitro and in vivo experiments demonstrated that RKIP was a potential targeting gene in the occurrence of metastasis and chemoresistance driven by KRAS in PDAC. Taken together, we established a novel link between the KRAS/ERK signaling axis and impairment of the RKIP tumor suppressor and elucidated a mechanism underlying tumor metastasis and resistance to chemotherapy in pancreatic cancer. Thus, these findings warrant further investigation on the potential development of RKIP-based therapeutic approaches in pancreatic cancer.
Material and Methods

Cell culture
The human pancreatic cancer cell lines (PANC-1 
Co-immunoprecipitation (co-IP)
Cell extracts incubated with anti-KRAS antibody (Millipore) were precipitated with protein G-agarose beads (Millipore). Aliquots of the immunoprecipitated proteins were separated by SDS-PAGE, and proteins were analyzed by Western blot as described above.
Genotyping of KRAS, plasmids, siRNAs and stable cell lines
The genomic DNA was extracted from fresh pancreatic cancer tissue using the TIANamp Genomic DNA Kit (TIAN-GEN BIOTECH, Beijing, China). Then the DNA was sent to the Huada Gene Company (Shenzhen, China) and analyzed for KRAS mutations in exons 1-4 by bidirectional sequence analysis. To construct overexpression plasmids, the wild-type KRAS and RKIP DNA fragments were generated by PCR with the isolated genomic DNA of BxPC-3 cells as the template. And the KRAS G12D mutant DNA fragments were amplified from cDNA of PANC-1 cells by PCR. All the DNA fragments were cloned into pcDNA3.1(1) vectors (primers for plasmids are described in Supplementary Table S3 ) and the accuracy of the clones was confirmed by DNA sequencing. Lentiviral shRNA virus carrying firefly luciferase for human KRAS and RKIP and RKIP-specific siRNAs were purchased from GenePharma (Shanghai, China). The shRNA sequences (RKIP-specific siRNAs are the same as shRKIP) for targeting KRAS and RKIP genes are shown in Supplementary Table S3 . The lentiviral vector was used to infect targeted cells. Stable cells were generated by selection with puromycin (1 lg/ml, Invitrogen).
Cell proliferation assay, invasion and migration assays
Cell viability was determined using the MTT assay according to the manufacturer's instructions. Briefly, cells were seeded in triplicate at a density of 1 3 10 4 per well (or 1.5 3 10 4 per well for gemcitabine and cisplatin treatment) in 96-well plates. After the indicated incubation period, the medium was removed, and the MTT labeling reagent was added to the surviving cells, and the cells were incubated at 378C for 2 hr. Next, the absorbance of stained cells was measured at 570 nm and the IC 50 was calculated with GraphPad Prism software. At least three-independent experiments were performed. For invasion assay, cells were harvested after serum-free starvation for 12 hr and were resuspended in serum-free DMEM media. Cells (2 3 10 4 ) were seeded in a Matrigelcoated 8-mm pore chamber (Corning, Corning Life Sciences, MA, USA). Complete growth media was added to the bottom chamber as an attractant. After incubation for 48 hr at 378C, the invading cells at the bottom of the filter were fixed with 4% paraformaldehyde and were stained in dye solution containing 20% methanol and 0.1% crystal violet. The number of invading cells in each chamber was quantified by counting nine randomly chosen fields under 200 3 magnification using a bright-field microscope. Each condition was performed in duplicate, and the average number of cells per field was calculated. Experiments were repeated three times. The migration assay was the same as the invasion assay, except that no Matrigel was used and the cell permeating time was 24 hr.
Animal experiments
All mouse experiments were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Animal Care and Use Committee of Sun Yat-sen University. To study the effect of RKIP on tumorigenesis, chemoresistance and metastasis and KRAS's effect in mediating RKIP's function in chemoresistance and metastasis, we conducted tumor xenograft studies and tail vein injection studies. Before formal experiments, the tumor metastasis ability of pancreatic cancer cell lines has been examined. SW1990-injected mice displayed more obvious metastases in lung and liver than PANC-1 (data not shown). So we chose SW1990 for further study. To establish SW1990 tumor xenografts, SW1990-nc, SW1990-shKRAS, SW1990-shRKIP and SW1990-shKRAS 1 shRKIP cells (2 3 10 6 cells in 0.2 ml of PBS) were injected subcutaneously into the right flank of 4-week-old female BALB/c nude mice. When tumors became palpable (approximately 5 days after cell implantation), these mice were treated with gemcitabine (50 mg/kg) or vehicle control (PBS) thriceweekly by intraperitoneal injection. At 21 days after injection, the mice were sacrificed. Tumor size was measured with a caliper daily, and the tumor volume was calculated using the equation tumor volume (mm 3 ) 5 (length in mm) 3 (width in mm) 2 /2. The tumorigenesis experiments were performed as described for the chemoresistance experiments, except that no drugs were used. For experimental metastasis assays, each mouse was injected with 1 3 10 6 cells via the tail vein. An IVIS Spectrum system (Caliper Life Sciences, PerkinElmer, MA, USA) was used to observe the quantity and location of metastatic tumors in live mice 4 weeks after the cells were injected. After an intravenous injection of luciferin (150 mg/ kg), the mice were anesthetized with 2% isoflurane. And the bioluminescence of metastatic tumors was detected. Then the mice were sacrificed. The subcutaneous tumors, lungs and livers were removed, fixed, and paraffin-embedded. To examine the metastasis, sections of the lungs and livers were stained with hematoxylin and eosin (H&E).
Immunohistochemistry and assessment of immunostaining
The tissues were embedded in paraffin and sectioned into 4-lm-thick slices for immunohistochemical staining. Following deparaffinization, the sections were incubated with primary antibodies overnight at 48C. Then, horseradish peroxidase-conjugated secondary antibodies were added, and the sections were incubated at 378C for 1 hr. Then, the slides were incubated in diaminobenzidine solution for 5 min and counterstained with hematoxylin for 1 min. The degree of immunostaining was evaluated and scored by twoindependent observers, who scored both the percentage of positively stained cells (0, <5%; 1, 5-35%; 2, >35-65% and 3, >65%) and the intensity of positive staining (0, negative; 1, weak; 2, moderate and 3, strong). The staining index (SI) was calculated by adding the two scores. For the statistical analysis, scores were defined as follows: positive (SI score of 3 or more) or negative (SI score below 3). 26 
Statistical analysis
The data were expressed as the mean 6 SD, and the differences between any two groups were compared by t-tests. The associations between KRAS expression and RKIP expression were analyzed using the Spearman rank correlation test. Pearson's correlation analysis was applied to evaluate the correlation coefficiency of KRAS and RKIP mRNA levels in the fresh PDAC tissue. Kaplan-Meier curve analysis was used to examine the association of KRAS and RKIP expression and survival time of tumor resected patients. The prognostic value was determined by univariate and multivariate Cox regression analysis. One-way ANOVA was used when >2 groups were examined. All of the statistical analyses were performed using SPSS17.0 software. Statistical significance was defined as p < 0.05.
Results
Inverse correlation between KRAS and RKIP expression
Forty-one fresh PDAC tumor tissues that we collected were detected for KRAS and RKIP mRNA expression levels. KRAS mRNA level is higher in PDAC tumor than in adjacent nontumor tissue (2.262 vs. 0.920, p < 0.05; Fig. 1a) , while RKIP mRNA level is lower in PDAC tumor than in adjacent nontumor tissue (1.110 vs. 2.348, p < 0.05; Fig. 1b) . A negative correlation between KRAS and RKIP mRNA expression levels was shown in PDAC tumor tissue (correlation index-5 20.596; p < 0.05). To further investigate the relationship between KRAS mutant status and RKIP expression in pancreatic cancer, 41 patients with PDACs were evaluated for the presence of KRAS mutations. This genotyping revealed 32 patients (78%) with KRAS mutations and the other 9 patients (22%) with wild-type KRAS. We further detected KRAS mutant status and RKIP mRNA of the tumors. The subsequent statistical analysis showed that no difference was found in RKIP mRNA between the mutant KRAS PDACs and the wild-type KRAS PDACs (p > 0.05; Fig. 1c ). In addition, there was no significant difference in KRAS mRNA in accordance to the status of KRAS mutations (p > 0.05; Fig. 1d ).
Tissue microarray (TMA) of 100 well-characterized PDACs was further analyzed to verify the relationship between the KRAS and RKIP. All tissues were analyzed by immunohistochemistry using anti-KRAS and anti-RKIP antibodies and graded based on staining intensity. Both KRAS and RKIP proteins were mainly localized in the cytoplasm. Among these 100 PDAC serial sections, 53% of the sections (53 of 100) that exhibited KRAS-positive were RKIP-negative, whereas 16 out of 100 cases with negative KRAS staining were positive for RKIP. Moreover, 14% of tumors exhibited positive staining for both KRAS and RKIP, and staining for both KRAS and RKIP was negative in 17% of the cases. Two representative cases with assonant staining were shown in Figure 1e . Spearman correlation analysis indicated that KRAS expression was inversely correlated with RKIP expression (r 5 20.283, p 5 0.004; Fig. 1f ). By contrast, RKIP staining is stronger than KRAS staining in adjacent non-tumor tissue ( Supplementary Fig. S1a ). The expression levels of KRAS and RKIP in pancreatic cancer cell lines were also inversely correlated ( Supplementary Fig. S1b ).
Clinical significance of KRAS and RKIP
Both KRAS and RKIP expression closely correlated with lymph node and distant metastasis (p < 0.05, Supplementary Table S2) showed that KRAS expression, RKIP expression, LN metastasis and distant metastasis were independent prognostic factors of patients' overall survival (OS). Furthermore, survival analysis by the Kaplan-Meier method showed that tumor resected patients with positive KRAS expression in their pancreatic tumors had a shorter median survival time (8.9 months) than those with negative KRAS expression, whose median survival time was 15.6 months (p < 0.001; Fig. 1g) . The median survival time of patients with RKIP-positive tumors was 13.5 months, compared to 9.4 months for patients with RKIP-negative tumors (p < 0.05; Fig. 1h) . Interestingly, the median survival time was 8.4 months for patients with KRAS-positive/RKIP-negative tumors and 18.2 months for patients with KRAS-negative/RKIP-positive tumors (p < 0.001; Fig. 1i ). Similar results were obtained from the patients with postoperative chemotherapy. As shown in postoperative chemotherapy patients, the survival analysis showed a significantly shorter median survival time for patients with tumors exhibiting positive KRAS expression than for those with negative KRAS expression (p < 0.01; Fig. 1j ). In contrast, RKIP-positive tumors resulted in better survival for patients receiving chemotherapy (p < 0.01; Fig. 1k ). The median survival time was 9.4 months in the KRAS-positive/RKIP-negative group and 20.1 months in the KRAS-negative/RKIP-positive group (p < 0.001; Fig. 1l ).
KRAS regulates RKIP expression through the ERK pathway in pancreatic cancer cells
To select shRNAs against human KRAS or RKIP, PANC-1 and SW1990 cell lines were stably transfected with pGLVH1 vectors expressing shRNAs. As shown in Supplementary Figures S2a-S2d, shKRAS2 and shRKIP2 were more efficient and used in the following experiments. The results showed that the expression of RKIP was induced in the shKRAS transfected PANC-1, SW1990 and BxPC-3 cells compared to the control cells (Fig. 2a) .We subsequently sought to identify the pathways downstream of KRAS that regulate RKIP expression. Because ERK and AKT phosphorylation are known to be activated by KRAS, 21 we investigated whether these two pathways regulate RKIP expression. The results showed that U0126 (an inhibitor of ERK) appreciably increased RKIP expression (Fig. 2b) , whereas LY294002 (an inhibitor of AKT) had no obvious influence on RKIP expression (Supplementary Fig. S3 ). Therefore, KRAS-regulated RKIP via ERK but not AKT activation. In agreement with the increase in RKIP protein levels, KRAS knockdown or ERK inhibition elevated RKIP mRNA levels (Figs. 2c and 2d ). To further demonstrate that RKIP is regulated by KRAS, PANC-1 and SW1990 cells were transiently transfected with plasmids overexpressing mutant KRAS, while BxPC-3 cells were transiently transfected with wildtype KRAS plasmids. The protein expression of RKIP substantially decreased after KRAS overexpression, and inhibition of the ERK pathway could restore RKIP expression (Figs. 2e and 2f) . Consistently, the downregulation of RKIP mRNA induced by KRAS overexpressing was abolished by the addition of ERK inhibitor U0126 (Figs. 2g and 2h ). All the band intensities measured by densitometry were shown in Supplementary Figure S4 . Since KRAS and RKIP proteins were both localized in the cytoplasm mainly, we speculated that whether there exists an interaction between KRAS and RKIP. Consequently, we detected co-immunoprecipitation of endogenous KRAS and RKIP proteins in PANC-1 or BxPC-3 cell lysates using a self-raised anti-KRAS antibody. However, immunoreactive signals of KRAS and RKIP were not detected in either PANC-1 or BxPC-3 cell, suggesting that mutant KRAS or wild-type KRAS did not interact with RKIP ( Supplementary Fig. S5 ).
The biological function of RKIP is regulated by KRAS in pancreatic cancer cells
To further investigate the role of RKIP in pancreatic cancer cells, PANC-1 and SW1990 cells were transfected with shRKIP for the stable downregulation of RKIP or were transiently transfected with pcDNA3.1(1)-RKIP to overexpress RKIP. As shown in Figures 3a and 3b , RKIP shRNA upregulated the mRNA and protein levels of the pro-metastatic factors Snail and Twist1 and the anti-apoptotic protein Bcl-2. In contrast, the mRNA and protein levels of Ecadherin (Ecad) and apoptotic Bax were downregulated by RKIP shRNA. Consistent with the knockdown results, transfection of PANC-1 and SW1990 with RKIP overexpression plasmids attenuated Bcl-2, Snail and Twist1 expression while simultaneously enhancing Bax and Ecad expression (Figs. 3c and  3d) . Thus, RKIP potently inhibits metastasis and resistance to apoptosis in pancreatic cancer cells. Next, we probed the biological characteristics of RKIP regulated by KRAS using Western blot. The results showed whether KRAS knockdown or ERK inhibition was found to express high levels of RKIP, Ecad and Bax, as well as low levels of Snail, Twist1 and Bcl-2. Interestingly, the protein expression pattern was markedly reversed by knockdown of RKIP (Figs. 3e and 3f) . Conversely, opposing effects occurred with KRAS overexpression, and the protein expression patterns were reversed by ERK pathway inhibition (Fig. 3g) . Moreover, downregulation of KRAS and inhibition of the ERK pathway resulted in decreased phosphorylation of ERK1/2, accompanied by reduction in Snail expression. By contrast, KRAS overexpression-enhanced ERK1/2 phosphorylation increased Snail expression, which was impeded by ERK pathway inhibition. The bands were quantified and shown in Supplementary Figure S6 .
KRAS regulates RKIP-dependent cell migration, invasion and chemosensitivity in vitro
We determined whether RKIP repression was the underlying cause of the KRAS-mediated facilitation of cell migration and invasion in vitro using the Transwell assays. KRAS knockdown reduced the number of migrating and invading cells compared to the mock control, whereas RKIP knockdown increased the number of cells. Importantly, the impact of KRAS silencing was efficiently blunted by RKIP silencing (Fig. 4a) . In addition, shRNA-mediated KRAS knockdown significantly inhibited cell growth. However, there was no notable difference between the control and RKIP shRNAtreated groups (Fig. 4b) . We then assessed chemotherapy sensitivity of the tumor cells using an MTT assay. The RKIPsilenced cells displayed much greater chemoresistance than the control cells when treated with two conventional chemotherapeutic agents (gemcitabine and cisplatin). As expected, the KRAS shRNA knockdown cells exhibited much more sensitive to gemcitabine and cisplatin. Moreover, RKIP silencing by siRNA significantly attenuated the impact of KRAS silencing on chemotherapeutic drug sensitivity (Fig. 4c) . Therefore, KRAS regulates chemosensitivity partly via a RKIP-dependent mechanism. 
RKIP knockdown inhibits KRAS-mediated tumor metastasis and chemoresistance in vivo
To unequivocally demonstrate the function of the KRAS-RKIP axis in metastatic colonization and drug-resistance, a lentiviralmediated knockdown system was used to knockdown RKIP in SW1990-shKRAS cells. The SW1990-shKRAS cells had fewer lung and liver metastases than controls, whereas the knockdown of RKIP resulted in a significant increase in the number of metastatic foci in lung and liver. Moreover, a dramatic upregulation in the number of foci in the lungs and livers of mice injected with KRAS/RKIP knockdown cells in comparison to the shKRAS lungs (Fig. 5) . Quantification of luciferase activity further confirmed the effect of KRAS-RKIP axis on metastasis of pancreatic cancer cells (Supplementary Fig. S7 ). To evaluate in vivo tumor growth, we performed xenograft studies. In total, 2 3 10 6 cells of each cell line were subcutaneously injected into the right flank of immunodeficient mice, and tumor growth was determined (Fig. 6a) . We observed that shKRAS-injected mice displayed an obvious attenuation in tumor growth, whereas RKIP silencing had no visible effect on tumor growth (Figs. 6b  and 6c) . To assess the chemosensitivity of tumor cells, we injected BALB/c nude mice with 2 3 10 6 cells and then evaluated their response to gemcitabine treatment. When the xenograft tumors became palpable, mice were treated intraperitoneal injection (i.p.) with gemcitabine (50 mg/kg) or PBS (vehicle) thrice-weekly, and tumor sizes were recorded. On Day 14, mice were sacrificed, and tumors were resected and weighted. We found that shKRAS displayed a significantly stronger effect in reducing tumor growth compared to shcon. However, the tumors were significantly larger in the shRKIP group relative to the control group (Fig. 6d) . In parallel, this trend was also confirmed by the tumor growth rate and dissected weights (Supplementary Fig. S8 ). Given that there were no significant differences between shRKIP and shcon in tumorigenesis, we concluded that knockdown of RKIP is critical for blocking tumor chemosensitivity. Again, the impact of shKRAS could be abolished by ablating RKIP expression. In addition, immunohistochemical staining of KRAS, RKIP, Ecad, Snail, Twist1, Bcl-2 and Bax was performed in samples from the xenograft tumors (Fig. 6e) , and the results were consistent with the Western blot assay. Importantly, the inverse correlation between the expression of KRAS and RKIP was detected in sections containing samples derived from shcon and shKRAS xenograft tumors, which further supports our viewpoint.
Discussion
PDAC is a devastating disease with poor survival rates. The major reasons for the high mortality of PDAC are the high metastatic and chemoresistance abilities. KRAS codes RAS protein and plays an important role in cell proliferation and differentiation. 27 When there is no extracellular signal stimulation, RAS protein combines with guanosine diphosphate (GDP) in the inactivation state. While extracellular signal stimulation exists, RAS protein combines with guanosine triphosphate (GTP) in the activated state and interacts with multiple downstream effectors that regulate cell growth and differentiation. KRAS mutations are recognized as the most frequent oncogenic event in PDAC. [28] [29] [30] Once KRAS mutations occur, RAS protein is accumulated in its active conformation, leading to aberrant cellular proliferation, suppression of apoptosis and promotion of metastasis. 20 Direct suppression of KRAS mutations or applying RAS protein blocker seems like inhibiting the pancreatic cancer cell proliferation, and can even reverse the malignant characteristics. 31 However, all these results are not satisfactory. 32, 33 Therefore, illumination of RAS protein downstream signaling pathways is an important prerequisite for effective intervention of KRAS and expected to become the treatment target of PDAC. Recently, it was reported that expression of RKIP is lost in PDAC. 17 Mounting evidence indicates that RKIP is a modulator of cancer metastasis and chemoresistance by regulating EMT progression 34 and survival signaling cascades. 35, 36 Although RKIP interferes with the RAS-target Raf-1, 6 no direct regulatory effect of KRAS on RKIP has been illuminated. Inspired by the previous findings, we speculated that cross-talk may occur between KRAS and RKIP.
Our study showed a negative correlation between KRAS and RKIP mRNA expression in PDAC fresh tissue. Genotype analysis demonstrated KRAS mutations did not have impact on RKIP mRNA expression levels comparing against wild-type KRAS, similar to the observation in colorectal cancer. 37 This is probably due to other signal transmission pathways exist to regulate RKIP in addition to the KRAS-ERK pathway that we verified in our study. 38, 39 In accord with the mRNA results of fresh PDAC tissue, PDAC tissue microarray and pancreatic cancer cell lines analysis confirmed the reversed correlation between KRAS and RKIP protein expressions. All these suggest that KRAS has a physiological role in regulating RKIP levels in PDAC. The regulatory relationship between KRAS and RKIP was further clarified in both mutant KRAS pancreatic cell lines PANC-1 and SW1990, and wild-type KRAS pancreatic cell line BxPC-3. Inhibition of KRAS significantly increased RKIP expression, and ectopic expression of KRAS markedly reduced the levels of RKIP. A previous study showed that ERKmediated RKIP phosphorylation neutralized the inhibitory effects of RKIP. 40 In our study, we found that RKIP expression is inhibited by the activated ERK signaling pathway, demonstrating that the KRAS-ERK pathway is of particular importance in RKIP regulation. In addition, our research shows that enhanced or reduced Snail expression is regulated by an activated or inactivated ERK pathway, respectively. Our results align with previously published data showing that the expression of Snail is downregulated through the inhibition of the ERK pathway. 41 Given that Snail is a transcriptional repressor of RKIP, 39 we hypothesized that activated KRAS-induced ERK pathway activation increases the expression of Snail, which further represses the transcriptional expression of RKIP, and the depressed RKIP in turn induces Snail expression in a feedback loop, as previously reported. 42 Previous studies have shown that RKIP functions as a tumor suppressor. In our study, the downregulation of RKIP was associated with poor survival of PDAC, which is in agreement with previous studies that PDAC patients with negative RKIP had a poor prognosis. 43 However, the functional role of RKIP in PDAC has not been clearly elucidated. Recently, several studies have reported that an increasing number of pivotal EMT-related transcription factors, such as Snail and Twist1, along with decreased expression of Ecad, are involved in EMT initiation during tumor metastasis. 44, 45 It has become evident that chemoresistance is strongly associated with defects in the regulation of cell death and apoptosis. 46 Thus, upregulation of the antiapoptotic protein Bcl-2 and downregulation of proapoptotic Bax play important roles in increased chemoresistance. 47 In this context, we demonstrated the impact of RKIP on inhibiting the metastasis and increasing the chemosensitivity of pancreatic cancer cells. Moreover, KRAS functions as a repressor of RKIP. We propose a molecular model whereby activated KRAS binds to Raf, which subsequently directly activates MEK via phosphorylation. Then, MEK1/2 phosphorylates and thereby activates ERK. Upon activation, ERK can repress RKIP expression, consequently enhancing the expression of genes necessary for metastasis and the development of chemoresistance and simultaneously downregulating the corresponding suppressor genes (Supplementary Fig. S9 ). In our study, we have confirmed the effects of the KRAS-RKIP axis in vitro and in vivo. RKIP-downregulated cells show higher migration and invasion capacities and a clear resistance to drug treatment in vitro. Further in vivo experiments in mice demonstrated that shRKIP-promoted metastasis to lung and liver and shRKIP-inhibited sensitivity to gemcitabine were greater than those of shcon. In contrast, knockdown of KRAS displayed the reverse outcome relative to RKIP knockdown. Furthermore, silencing RKIP could significantly rescue the effect of KRAS inhibition on pancreatic cancer cell metastasis and chemoresistance. Importantly, no impact of RKIP expression on the cell proliferation and the tumor growth were observed in vitro and in vivo, which is consistent with previous results. 48 Collectively, these findings strongly indicate that a pivotal role for RKIP in KRAS-mediated metastasis promotion and chemosensitivity suppression.
In summary, we demonstrate a new pathway through which KRAS promotes metastasis and chemoresistance in PDAC, which was achieved mainly by the regulation of RKIP through MAPK-ERK, thus offering evidence for potential development of RKIP-based therapeutic approaches in pancreatic cancer. Therefore, enhancing RKIP expression in PDAC cells would be a promising therapy strategy. 
